We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biopharma Receives Positive EMA Opinion on Orphan Designation for Pancreatic Cancer Treatment
Product News

Biopharma Receives Positive EMA Opinion on Orphan Designation for Pancreatic Cancer Treatment

Biopharma Receives Positive EMA Opinion on Orphan Designation for Pancreatic Cancer Treatment
Product News

Biopharma Receives Positive EMA Opinion on Orphan Designation for Pancreatic Cancer Treatment


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Biopharma Receives Positive EMA Opinion on Orphan Designation for Pancreatic Cancer Treatment"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has granted a positive opinion for an Orphan Drug Designation (ODD) status to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.

Receiving the ODD status means that Prestige BioPharma would receive numerous benefits including the exclusive rights to sale for 10 years after a successful regulatory approval in the future. Prestige BioPharma’s PBP1510 has already received ODD status from the US Food and Drug Administration (FDA) and the Korean Ministry of Food and Drug Safety during June and July 2020 respectively.

Dr. Lisa Park, CEO of Prestige Bio Pharma said, “The positive opinion of EMA COMP confirms that PBP1510 has once again successfully established to be a globally innovative first-in-class drug. It is expected that the development of PBP1510 will gain more resilience and will have a positive effect in terms of clinical trial procedures and product approval.”

The positive opinion issued by COMP will be sent to the European Commission which is expected to grant the orphan designation within 30 days.


Advertisement